Quidel Corporation v. Siemens Medical Solutions USA, Inc.

CourtDistrict Court, S.D. California
DecidedSeptember 27, 2019
Docket3:16-cv-03059
StatusUnknown

This text of Quidel Corporation v. Siemens Medical Solutions USA, Inc. (Quidel Corporation v. Siemens Medical Solutions USA, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Quidel Corporation v. Siemens Medical Solutions USA, Inc., (S.D. Cal. 2019).

Opinion

5 6

7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA

10 QUIDEL CORPORATION, Case No. 16-cv-3059-BAS-AGS 11 Plaintiff, ORDER DENYING PLAINTIFF’S 12 MOTION TO EXCLUDE REBUTTAL OPINIONS AND 13 v. TESTIMONY OF ARTHUR L. CAPLAN 14 SIEMENS MEDICAL SOLUTIONS USA, INC., et al., [ECF No. 151] 15 Defendants. 16 17 18 19 Plaintiff Quidel Corporation and Defendants Siemens Medical Solutions USA, 20 Inc. and Siemens Healthcare Diagnostics Inc. have filed motions seeking to exclude 21 the opinions of the other party’s expert. The Court first turns to Plaintiff’s motion to 22 exclude the rebuttal opinions and testimony of Defendants’ expert Dr. Arthur L. 23 Caplan. (“Caplan Mot.,” ECF No. 151.) For the foregoing reasons, the Court denies 24 the Motion. 25 I. Relevant Background1 26 On January 11, 2019, the deadline for expert designation disclosure, Quidel 27 1 designated Dr. George J. Kahaly as a scientific expert, and submitted his opening 2 expert report. (“Roosevelt Decl.,” ECF No. 151-2, at ¶ 2.) Dr. Kahaly opined 3 generally that Defendants’ assay IMMULITE is “not specific for the detection of 4 TSI.” (“Kahaly Report,” Exhibit 32 to ECF 156-1, at 23.) He relied, inter alia, on 5 two publications authored by him and other scholars: 6 • T. Diana, C. Wuster, M. Kanitz, G. Kahaly, Highly variable sensitivity 7 of five binding and two bio-assays, Journal of Endocrinological 8 Investigation (April 2016); and 9 • T. Diana, C. Wuster, P. Olivo, A. Unterrainer, J. Konig, M. Kanitz, A. 10 Bossowski, B. Decallonne, G. Kahaly, Performance and Specificity of 11 Immunoassays for TSH Receptor Antibodies: A Multicenter Study, 12 European Thyroid Journal (August 2017). 13 (Id. at 27.) The Court will refer to the two studies as “Diana 2016” and “Diana 2017” 14 respectively. Diana is listed as the lead author for both studies, but Kahaly also 15 participated in the studies and is listed as an author for both. 16 On March 29, 2019, the deadline for rebuttal expert disclosures, Defendants 17 served the Expert Rebuttal Report of Dr. Arthur L. Caplan. (Roosevelt Decl. ¶ 3.) 18 Caplan’s report was submitted “to respond to and rebut the opinions offered by 19 Kahaly in this case.” (“Caplan Report,” Exhibit A to ECF No. 153, at 2.) In his 20 report, Caplan provides that he was advised that Kahaly’s opinions largely depend 21 on Diana 2016 and Diana 2017. Caplan wrote the report to address the adequacy of 22 the authors’ disclosures made in the two publications and how this affected the 23 publications’ scientific integrity. (Id.) Caplan was provided information regarding 24 Quidel’s relationship with Kahaly and the other authors. (Id. at 6–10.) Caplan 25 believes that the relationships were not sufficiently disclosed to the publisher before 26 the studies were published. Specifically, in the journals’ “conflict of interest” 27 sections for both studies, Diana and Kanitz stated they had “nothing to disclose” and 1 Kahaly said he “consults for Quidel.” (Id. at 12, 14.)2 Caplan opined that the conflict 2 of interest disclosures “are inconsistent with widely accepted ethical disclosure 3 standards, the represented disclosure standards of the two publishing journals, and 4 [the Johannes Gutenberg University Medical Center]’s disclosure standards as stated 5 by Kahaly.” (Id. at 15.) According to Caplan and the information he was provided, 6 Quidel “funded both studies and paid for Diana [and Kanitz] to work full time on 7 Quidel-funded studies since 2011” and this should have been disclosed. (Id. at 15, 8 16.) The studies were “initialed by Quidel, supervised by Quidel, and resulted in 9 findings that directly benefited Quidel and its commercial interests.” (Id. at 16.) This 10 adversely affects the scientific integrity of the studies. (Id.) In sum, “Kahaly’s expert 11 opinions have limited (if any) probative value, particularly to the extent his opinions 12 rely on the Diana 2016 and Diana 2017 publications.” (Id. at 22.) 13 II. Analysis 14 Quidel seeks to exclude the opinions and testimony of Dr. Caplan. Quidel’s 15 argument is three-fold: first, Dr. Caplan’s rebuttal opinions are not actually made in 16 rebuttal, second, Dr. Caplan’s opinions do not meet the Daubert standard of 17 reliability and relevance, and third, Dr. Caplan’s opinions are likely to mislead and 18 confuse the jury and will encroach on the jury’s function to make credibility 19 determinations. 20 A. Whether Caplan’s Report is Appropriately a Rebuttal Report 21 1. Legal Standard for Rebuttal Reports 22 Expert rebuttal reports must be “intended solely to contradict or rebut evidence 23 on the same subject matter identified by another party” in that other party’s expert 24 25 2 Defendants provide an in-depth background section laying out the details of Kahaly and Quidel’s 26 relationship, along with over a dozen exhibits providing evidence of the relationship. (“Caplan Opp’n,” ECF No. 154, at 3–9; ECF No. 154-1.) The details of the relationship are irrelevant. What 27 is relevant is that Kahaly had a relationship with Quidel before he conducted the studies, he 1 disclosures. Fed. R. Civ. P. 26(a)(2)(D)(ii). The phrase “same subject matter” should 2 be read narrowly because a broad reading that “encompass[es] any possible topic that 3 relates to the subject matter at issue[ ] will blur the distinction between ‘affirmative 4 expert’ and ‘rebuttal expert.’” Vu v. McNeil–PPC, Inc., No. CV 09–1656, 2010 WL 5 2179882, at *3 (C.D. Cal. May 7, 2010). “Accordingly, a careful analysis of each of 6 the Plaintiff’s expert[’]s proposed testimony and the corresponding [Defendant’s] 7 expert[’]s rebuttal testimony is required to determine if the rebuttal testimony is 8 proper.” Hellman–Blumberg v. Univ. of Pac., No. 12–cv–00286, 2013 WL 3422699, 9 at *2 (E.D. Cal. July 8, 2013). 10 If a disclosed rebuttal expert is not proper, “Rule 37 ‘gives teeth’ to Rule 26’s 11 disclosure requirements by forbidding the use at trial of any information that is not 12 properly disclosed.” Goodman v. Staples the Office Superstore, LLC, 644 F.3d 817, 13 827 (9th Cir. 2011) (citing Yeti by Molly, Ltd. v. Deckers Outdoor Corp., 259 F.3d 14 1101, 1106 (9th Cir.2001)). Rule 37(c)(1)’s exclusion sanction is mandatory unless 15 failure to disclosure is substantially justified or harmless. Fed. R. Civ. Pro. 37(c)(1). 16 2. Analysis 17 Quidel argues Caplan is not a rebuttal expert to Kahlay because the report is 18 not a response to Kahaly’s. Specifically, Caplan opines on conflict of interest 19 disclosures, but Kahaly has not been designated and is not providing expert opinions 20 on conflict of interest disclosures. (Caplan Mot. at 6.) 21 The Court disagrees. Caplan is responding to a portion of Kahaly’s report. 22 Kahaly relies on and cites Diana 2016 and Diana 2017 in his report. (Kahaly Report 23 at 27.) Caplan opines that the studies are flawed, and therefore, the report is flawed 24 to the extent it relies on the studies. The Court finds that this is sufficiently a rebuttal 25 report. Indeed, there is no requirement that “a rebuttal expert read[] the opening 26 expert report cover to cover, and then write[] a rebuttal report outlining each and 27 every criticism of the opening expert’s opinions.” Pinterest, Inc. v. Pintrips, Inc., 1 responds to what Defendants deem to be a “fundamental flaw” in Kahaly’s report. 2 Id. “That [Caplan’s] work was targeted at a specific topic identified by counsel—as 3 opposed to addressing all purported defects in the [Kahaly report]—makes 4 [Caplan’s] testimony no less proper as rebuttal evidence.” Id. Rebuttal testimony is 5 permitted to “question the assumptions and methods” of an opposing expert.” 6 LaFlamme v. Safeway, Inc., No. 09-cv-514-ECR-VPC, 2010 WL 3522378, at *8 (D. 7 Nev.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Primiano v. Cook
598 F.3d 558 (Ninth Circuit, 2010)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Laro v. New Hampshire
259 F.3d 1 (First Circuit, 2001)
Goodman v. Staples the Office Super-Store, LLC
644 F.3d 817 (Ninth Circuit, 2011)
Cooper v. Brown
510 F.3d 870 (Ninth Circuit, 2007)
Estate of Henry Barabin v. Astenjohnson, Inc.
740 F.3d 457 (Ninth Circuit, 2014)
Veronica Ollier v. Sweetwater Union High School
768 F.3d 843 (Ninth Circuit, 2014)
In re Conagra Foods, Inc.
302 F.R.D. 537 (C.D. California, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Quidel Corporation v. Siemens Medical Solutions USA, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/quidel-corporation-v-siemens-medical-solutions-usa-inc-casd-2019.